Literature DB >> 10396300

Abnormal cell cycle regulation in malignancy.

M Dictor1, M Ehinger, F Mertens, J Akervall, J Wennerberg.   

Abstract

The cell cycle consists of an initial growth phase (G1), DNA replication (S), a gap phase (G2), and mitosis (M), after which the cell may differentiate or enter the resting state (G0). The cycle is driven by a number of positive and negative regulatory phosphorylation and dephosphorylation events, involving protein kinases, protein phosphatases, cyclins, cyclin-dependent kinases, and cyclin-dependent kinase inhibitors, that ultimately impinge on the activity of transcription factors. Unreplicated or damaged DNA blocks the progression of the cell cycle at checkpoints, including a late G1 checkpoint regulated by the dephosphorylated retinoblastoma protein and a late G2 checkpoint regulated by the phosphorylation of cyclin-dependent kinase 1 complexed with cyclin B. Many cell cycle regulator genes may be considered proto-oncogenes or tumor suppressor genes, and point mutations, amplifications, deletions, or rearrangements involving their loci, particularly those in the "RB pathway," are associated with various tumors. A number of molecular techniques may be used to detect genomic alterations or posttranscriptional modifications, but immunohistochemistry remains the most common method to determine expression levels of a regulatory protein. Multivariate analysis of the usefulness in prognosis has been applied most often for the general proliferation antigen Ki-67.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10396300

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  12 in total

1.  Novel genomic imbalances in B-cell splenic marginal zone lymphomas revealed by comparative genomic hybridization and cytogenetics.

Authors:  J M Hernández; J L García; N C Gutiérrez; M Mollejo; J A Martínez-Climent; T Flores; M B González; M A Piris; J F San Miguel
Journal:  Am J Pathol       Date:  2001-05       Impact factor: 4.307

2.  Expression of cyclins, p53, and Ki-67 in cervical squamous cell carcinomas: overexpression of cyclin A is a poor prognostic factor in stage Ib and II disease.

Authors:  Shigeki Shiohara; Tanri Shiozawa; Tsutomu Miyamoto; Yu-Zhen Feng; Hiroyasu Kashima; Miyuki Kurai; Akihisa Suzuki; Ikuo Konishi
Journal:  Virchows Arch       Date:  2005-05-13       Impact factor: 4.064

3.  Intratumoral heterogeneous expression of p53 correlates with p53 mutation, Ki-67, and cyclin A expression in endometrioid-type endometrial adenocarcinomas.

Authors:  Yu-Zhen Feng; Tanri Shiozawa; Akiko Horiuchi; Hsien-Chang Shih; Tsutomu Miyamoto; Hiroyasu Kashima; Akihisa Suzuki; Toshio Nikaido; Ikuo Konishi
Journal:  Virchows Arch       Date:  2005-07-14       Impact factor: 4.064

Review 4.  Human T-cell leukemia virus type 1 Tax and cellular transformation.

Authors:  Jean-Marie Peloponese; Takao Kinjo; Kuan-Teh Jeang
Journal:  Int J Hematol       Date:  2007-08       Impact factor: 2.490

5.  Deep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cells.

Authors:  Wei-Hua Dong; Qin Li; Xiao-Yan Zhang; Qing Guo; Huizheng Li; Tian-Yun Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

Review 6.  Cell cycle and no end.

Authors:  Mathewos Tessema; Ulrich Lehmann; Hans Kreipe
Journal:  Virchows Arch       Date:  2004-02-17       Impact factor: 4.064

7.  Expression of the cell cycle regulatory proteins p34cdc2, p21waf1, and p53 in node negative invasive ductal breast carcinoma.

Authors:  H P Kourea; A K Koutras; C D Scopa; M N Marangos; E Tzoracoeleftherakis; D Koukouras; H P Kalofonos
Journal:  Mol Pathol       Date:  2003-12

Review 8.  CDK/CCN and CDKI alterations for cancer prognosis and therapeutic predictivity.

Authors:  Patrizia Bonelli; Franca Maria Tuccillo; Antonella Borrelli; Antonietta Schiattarella; Franco Maria Buonaguro
Journal:  Biomed Res Int       Date:  2014-01-29       Impact factor: 3.411

Review 9.  The unpluggable in pursuit of the undruggable: tackling the dark matter of the cancer therapeutics universe.

Authors:  Richard J Epstein
Journal:  Front Oncol       Date:  2013-12-12       Impact factor: 6.244

10.  Proliferative activity (ki-67 expression) and outcome in high grade osteosarcoma: a study of 27 cases.

Authors:  R Jong; A M Davis; M G Mendes; J S Wunder; R S Bell; R Kandel
Journal:  Sarcoma       Date:  2000
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.